Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye d... LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.32 | 5.24433849821 | 25.17 | 27.57 | 23.52 | 335470 | 25.09970639 | CS |
| 4 | 1.16 | 4.57954994078 | 25.33 | 27.57 | 20.92 | 218263 | 23.71699273 | CS |
| 12 | -5.41 | -16.9592476489 | 31.9 | 32.64 | 20.92 | 161087 | 24.50263555 | CS |
| 26 | 3.9 | 17.2642762284 | 22.59 | 38.93 | 20.92 | 160607 | 27.24357138 | CS |
| 52 | 10.51 | 65.7697121402 | 15.98 | 38.93 | 14.42 | 164033 | 23.07231177 | CS |
| 156 | 10.51 | 65.7697121402 | 15.98 | 38.93 | 14.42 | 164033 | 23.07231177 | CS |
| 260 | 10.51 | 65.7697121402 | 15.98 | 38.93 | 14.42 | 164033 | 23.07231177 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
